[go: up one dir, main page]

DK1765290T3 - Stabiliserede overmættede faste oplösninger af steroid-lægemidler - Google Patents

Stabiliserede overmættede faste oplösninger af steroid-lægemidler

Info

Publication number
DK1765290T3
DK1765290T3 DK05718248T DK05718248T DK1765290T3 DK 1765290 T3 DK1765290 T3 DK 1765290T3 DK 05718248 T DK05718248 T DK 05718248T DK 05718248 T DK05718248 T DK 05718248T DK 1765290 T3 DK1765290 T3 DK 1765290T3
Authority
DK
Denmark
Prior art keywords
solid solutions
supersaturated solid
steroid drugs
stabilized supersaturated
stabilized
Prior art date
Application number
DK05718248T
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1765290(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of DK1765290T3 publication Critical patent/DK1765290T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK05718248T 2004-03-10 2005-03-10 Stabiliserede overmættede faste oplösninger af steroid-lægemidler DK1765290T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
DK1765290T3 true DK1765290T3 (da) 2009-11-02

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05718248T DK1765290T3 (da) 2004-03-10 2005-03-10 Stabiliserede overmættede faste oplösninger af steroid-lægemidler

Country Status (32)

Country Link
US (1) US8715735B2 (da)
EP (2) EP1765290B1 (da)
JP (1) JP5006185B2 (da)
KR (1) KR101210695B1 (da)
CN (1) CN1984644B (da)
AR (1) AR048500A1 (da)
AT (1) ATE442131T1 (da)
AU (1) AU2005221403B8 (da)
BR (1) BRPI0507342A (da)
CA (1) CA2558582C (da)
CR (1) CR8630A (da)
DE (1) DE602005016551D1 (da)
DK (1) DK1765290T3 (da)
EA (1) EA012746B1 (da)
EC (1) ECSP066902A (da)
ES (2) ES2332229T3 (da)
GT (1) GT200500045A (da)
HR (1) HRP20090614T1 (da)
IL (1) IL177894A0 (da)
MY (1) MY142989A (da)
NO (1) NO20064473L (da)
NZ (1) NZ549793A (da)
PA (1) PA8626101A1 (da)
PE (1) PE20060016A1 (da)
PL (1) PL1765290T3 (da)
PT (1) PT1765290E (da)
RS (1) RS51076B (da)
SI (1) SI1765290T1 (da)
SV (1) SV2005002044A (da)
TW (1) TWI345986B (da)
UY (1) UY28803A1 (da)
WO (1) WO2005087199A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
CN101232869B (zh) * 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 局部给药的凝胶组合物
EP1904028A1 (en) * 2005-06-16 2008-04-02 Warner Chilcott Company Inc. Estrogen compositions for vaginal administration
WO2007128350A1 (en) * 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
ES2779826T3 (es) 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
CN101677994B (zh) * 2007-04-11 2015-07-22 药品生产公司 褪黑激素片剂及制备和使用的方法
US20110097405A1 (en) * 2008-02-13 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
WO2009113522A1 (ja) * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
MX342377B (es) 2008-05-02 2016-09-27 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
CA2739887A1 (en) * 2008-10-10 2010-04-15 Teva Women's Health, Inc. Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
EP2398461A1 (en) * 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
HK1216240A1 (zh) 2012-11-14 2016-10-28 W. R. Grace & Co.-Conn. 含有生物活性材料与无序无机氧化物的组合物
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11077086B2 (en) 2014-07-21 2021-08-03 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
WO2018149755A1 (en) * 2017-02-14 2018-08-23 Dsm Ip Assets B.V. Water dispersible formulations
EA201991798A1 (ru) * 2017-02-14 2019-12-30 ДСМ АйПи АССЕТС Б.В. Стабильные при хранении составы
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
ATE102022T1 (de) 1990-08-30 1994-03-15 Senju Pharma Co Zusammensetzung zur kontrollierten abgabe von medikamenten.
DE69016788T2 (de) * 1990-11-29 1995-06-22 Faulding F H & Co Ltd Verfahren zur Herstellung von Flüssigkeiten enthaltenden Pulvern.
DE4326240A1 (de) 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
RS50262B2 (sr) 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
KR100913910B1 (ko) 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
AU2003263663A1 (en) 2002-09-05 2004-03-29 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16- substituted testosterone analogues
WO2004041289A1 (en) 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
EP1601347A1 (en) * 2003-02-19 2005-12-07 LifeCycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion

Also Published As

Publication number Publication date
AU2005221403A1 (en) 2005-09-22
TW200600116A (en) 2006-01-01
JP5006185B2 (ja) 2012-08-22
AU2005221403B8 (en) 2010-01-07
JP2007528389A (ja) 2007-10-11
EA200601588A1 (ru) 2007-02-27
IL177894A0 (en) 2006-12-31
PL1765290T3 (pl) 2010-02-26
EP2087883A1 (en) 2009-08-12
CA2558582A1 (en) 2005-09-22
HRP20090614T1 (hr) 2009-12-31
EP1765290B1 (en) 2009-09-09
UY28803A1 (es) 2005-10-31
ES2332229T3 (es) 2010-01-29
HK1103660A1 (en) 2007-12-28
ES2390406T3 (es) 2012-11-12
DE602005016551D1 (de) 2009-10-22
AR048500A1 (es) 2006-05-03
SI1765290T1 (sl) 2010-01-29
MY142989A (en) 2011-02-14
WO2005087199A8 (en) 2007-03-29
WO2005087199A2 (en) 2005-09-22
CN1984644B (zh) 2010-12-08
PT1765290E (pt) 2009-11-23
CA2558582C (en) 2013-07-16
KR20060132999A (ko) 2006-12-22
AU2005221403B2 (en) 2009-12-10
CR8630A (es) 2007-06-06
ECSP066902A (es) 2006-12-20
PE20060016A1 (es) 2006-02-16
EP1765290A2 (en) 2007-03-28
CN1984644A (zh) 2007-06-20
EA012746B1 (ru) 2009-12-30
PA8626101A1 (es) 2006-07-03
US8715735B2 (en) 2014-05-06
SV2005002044A (es) 2005-11-04
US20050207990A1 (en) 2005-09-22
WO2005087199A3 (en) 2009-01-15
ATE442131T1 (de) 2009-09-15
NZ549793A (en) 2010-06-25
RS51076B (sr) 2010-10-31
EP2087883B1 (en) 2012-07-25
BRPI0507342A (pt) 2007-07-03
NO20064473L (no) 2006-10-10
GT200500045A (es) 2005-10-31
TWI345986B (en) 2011-08-01
KR101210695B1 (ko) 2012-12-11

Similar Documents

Publication Publication Date Title
DK1765290T3 (da) Stabiliserede overmættede faste oplösninger af steroid-lægemidler
NO20220690A1 (no) Stabil krystall av 4-oxoquinolinforbindelse
DK1992697T3 (da) Fremstilling af TNFR-Fc
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
DK1940351T3 (da) Formulering af småmolekylære lægemidler med langvarig frigørelse
DK1931350T3 (da) Administration af inhibitorer af dipeptidylpeptidase
DK1501485T3 (da) Tablet med höjt indhold af aktivt stof
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
DK2363414T3 (da) Stedstyret modifikation af FVIII
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
DK1778618T3 (da) Syntese af triethylentetraminer
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK1646413T3 (da) System til infusion af farmakologiske opløsninger
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1701698T3 (da) Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
DK1813678T3 (da) Fremgangsmåde til fremstilling af glycogen
EP1799271A4 (en) DISPOSAL OF POLYNUCLEOTIDES
NO20043305D0 (no) Preparation of lodixanol
DK2110124T3 (da) Biotilgængelige faste dosisformer af metaxalon
DK2049123T3 (da) Forsinket-afgivelsesglucocorticoid-behandling af rheumatoid sygdom
DK1870460T3 (da) Fremgangsmåder til fremstilling af proteiner med tripelhelixstruktur
DK1541137T3 (da) Transdermalt delivery system af gestoden
EP1784181A4 (en) VEGF Inhibition